Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the ...

Novo Nordisk trades 32% below fair value with a 3.6% yield, semaglutide at 74% of sales, EPS rebound post '26, and pipeline ...

Eli Lilly (NYSE:LLY) is rapidly establishing itself as the leader in GLP-1 treatments for weight loss. Its Zepbound injection ...

NVO files an NDA with the FDA for once-weekly CagriSema, a combo obesity injection showing superior weight loss in obese patients in phase III studies.

The imminent Indian patent expiry of Novo Nordisk’s global blockbuster anti-diabetic and weight loss treatment drug – the GLP ...

Danish pharma giant Novo Nordisk's recent launch of Ozempic in India alongside a 37% price cut on Wegovy points out at more ...

In November 2025, US President Donald Trump announced transformative actions to lower prescription drug costs and secure the ...

The pills are expected to cost much less then shots of blockbuster drugs like Zepbound and Wegovy. Mr. Funk was the managing ...

CNBC's Annika Kim Constantino reports on Eli Lilly after the company said its closely watched obesity pill helped patients ...

But in rare cases, this class of drugs called GLP-1 agonists can come with a debilitating side effects. Chief among them is ...

Healthcare stocks haven't gotten a lot of love from investors in recent years. While the market has been strong and the S&P 500 has rallied by 84% in the past five years, the Health Care Select Sector ...

A handful of drugmakers have already disclosed pricing deals with the Trump administration and plan to sell certain drugs at a discount on TrumpRx, the White House's new direct-to-consumer website ...